XML 34 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue Recognition (Tables)
6 Months Ended
Jun. 30, 2023
Revenue Recognition  
Schedule of disaggregation of revenues by payer types

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended

​

Six months ended

​

​

June 30, 

​

June 30, 

​

​

2023

​

2022

​

2023

​

2022

(in thousands)

​

​

​

​

​

​

​

​

​

​

Insurance carriers

​

$

226,521

​

$

167,822

​

$

436,899

​

$

332,564

Laboratory and other partners

​

​

27,449

​

​

22,142

​

​

50,254

​

​

42,879

Patients

​

​

7,434

​

​

8,236

​

​

16,007

​

​

16,890

Total revenues

​

$

261,404

​

$

198,200

​

$

503,160

​

$

392,333

Schedule of total revenue by geographic area

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended

​

Six months ended

 

​

​

June 30, 

​

June 30, 

 

​

    

2023

    

2022

    

2023

​

2022

 

(in thousands)

​

​

​

​

​

​

​

​

​

​

​

United States

 

$

253,296

​

$

191,886

​

$

486,550

​

$

379,103

​

Americas, excluding U.S.

 

​

1,206

​

​

530

​

​

2,364

​

​

1,271

​

Europe, Middle East, India, Africa

 

​

5,620

​

​

3,736

​

​

10,816

​

​

7,427

​

Asia Pacific and Other

 

​

1,282

​

​

2,048

​

​

3,430

​

​

4,532

​

Total revenues

 

$

261,404

​

$

198,200

​

$

503,160

​

$

392,333

​

Schedule of beginning and ending balances of accounts receivable and deferred revenues

​

​

​

​

​

​

​

​

​

​

Balance at

​

Balance at

​

​

June 30, 

​

December 31,

(in thousands)

​

2023

​

2022

Assets:

​

​

​

​

​

​

Accounts receivable, net

​

$

260,065

​

$

244,385

Liabilities:

​

​

​

​

​

​

Deferred revenue, current portion

​

$

15,644

​

$

10,777

Deferred revenue, long-term portion

​

​

21,502

​

​

20,001

Total deferred revenues

​

$

37,146

​

$

30,778

Schedule of changes in the balance of deferred revenues

​

​

​

​

​

​

​

​

​

​

June 30, 

​

June 30, 

​

​

2023

​

​

2022

(in thousands)

​

​

​

Beginning balance

​

$

30,778

​

$

28,722

Increase in deferred revenues

​

​

17,402

​

​

14,974

Revenue recognized during the period that was included in
deferred revenues at the beginning of the period

​

​

(7,521)

​

​

(5,757)

Revenue recognized from performance obligations satisfied
within the same period

​

​

(3,513)

​

​

(1,209)

Ending balance

​

$

37,146

​

$

36,730